marked.bio

Company

Antengene Biologics

3 active trials that select patients by a biomarker on marked.bio, across 1 biomarker; 1 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

pembrolizumab 1

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

3 of 3 trials shown

  1. A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

    Not yet recruiting Phase 3 Antengene Biologics Started 2026Primary completion 2029-12 NCT07795346

    ATG-022docetaxelirinotecan

    … advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with positive CLDN18.2 expression.

    Claudin 18.2 expressionAdvanced Gastric or Gastroesophageal Junction Adenocarcinoma

  2. A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

    Recruiting Phase 1/2 Antengene Biologics Started 2026Primary completion 2027-09 NCT07327229

    ATG-022pembrolizumabCAPOX

    …tological confirmation of gastric cancer or gastroesophageal junction adenocarcinoma with CLDN 18.2 positive, HER2-negative and PD-L1 positive expression.

    Claudin 18.2 expressionUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

  3. A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors

    Recruiting Phase 1 Antengene Biologics Started 2023Primary completion 2027-12 NCT05718895

    ATG-022

    Dose Expansion Phase: Claudin 18.2 positive solid tumors.

    Claudin 18.2 expressionAdvanced/Metastatic Solid Tumors